Overview

Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
0
Participant gender:
All
Summary
The main objective of this study is to compare the antidepressant efficacy and safety of DVS-233 SR versus placebo in adult outpatients with Major Depressive Disorder.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Criteria
Inclusion Criteria:

- Outpatients

- Men and women age 18 years of age and older

- Women of childbearing potential participating in the study must have a negative serum
pregnancy test result at screening and use a medically acceptable form of
contraception

Exclusion Criteria:

- Treatment with DVS-233 SR at any time in the past

- Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within 90
days of study day 1

- Known hypersensitivity to venlafaxine (IR or ER)

- Significant risk of suicide based on clinical judgment, including common